Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

OncoPrescribe-SI

Advertisement

ERLEADA® (Apalutamide)

February 16, 2018April 5, 2020 RR FDA Approvals
Prostate Cancer

The FDA on February 14, 2018 approved ERLEADA® for patients with Non-Metastatic Castration Resistant Prostate Cancer (NM-CRPC). ERLEADA® is a product of Janssen Biotech Inc.

Related Posts:

  • ERLEADA® (Apalutamide)
  • FDA Approves ERLEADA® for Non-Metastatic Castrate…
  • 2021 ASCO GU Cancers Symposium: Apalutamide and Abiraterone…
  • Final Analysis Confirms Superior OS Benefit with…

Post navigation

FDA Approves ZYTIGA® for High-Risk Metastatic Castration-Sensitive Prostate Cancer
Long Term Disease Free Survival Benefit with Adjuvant NERLYNX® in HER2-positive Breast Cancer

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

Subscribe

Ad 1

OncoPrescribe-CDC

Advertisement

Ad 2

”Dictionary-of-Cancer-Terms-in-OncoPrescribe”/

Advertisement

Ad 3

OncoPrescribe-Ad

Advertisement

Ad 4

OncoPrescribe

Advertisement

  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved